Understand the source comparison
AOD-9604 for Cutting Cycle Peptides Research: Comparison
AOD-9604 Beta-3 adrenergic receptor agonist; activates HSL via cAMP/PKA pathway 2.6kg mean subcutaneous fat reduction (12 weeks, 10mg/day) No change in fasting glucose, insulin, or HbA1c Minimal; occasional injection-site erythema Selective lipolysis studies w
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- AOD-9604
- Beta-3 adrenergic receptor agonist; activates HSL via cAMP/PKA pathway
- 2.6kg mean subcutaneous fat reduction (12 weeks, 10mg/day)
- No change in fasting glucose, insulin, or HbA1c
- Minimal; occasional injection-site erythema
- Selective lipolysis studies without metabolic confounding
- Full-length hGH
- GH receptor activation; IGF-1-mediated signaling
- Significant lean mass gain + fat loss (dose-dependent)
- Elevated fasting glucose, reduced insulin sensitivity, fluid retention
- Carpal tunnel, joint pain, edema, impaired glucose tolerance
- Anabolic + lipolytic research requiring lean tissue accretion
- Fragment 177-191
- Structurally similar to AOD-9604; beta-adrenergic pathway
- Comparable in vitro lipolysis; limited human data
- Assumed neutral (no human trials completed)
- Unknown
- Theoretical alternative; lacks clinical validation
- CJC-1295
- GHRH analog; stimulates endogenous GH release
- Indirect lipolysis through pulsatile GH secretion
- Mild IGF-1 elevation; minimal glucose impact if dosed conservatively
- Injection-site reactions; rare vasodilation
- Studies examining natural GH pulse dynamics